How does brain insulin resistance develop in Alzheimer's disease?

  • De Felice F
  • Lourenco M
  • Ferreira S
  • 243


    Mendeley users who have this article in their library.
  • 85


    Citations of this article.


Compelling preclinical and clinical evidence supports a pathophysiological connection between Alzheimer's disease (AD) and diabetes. Altered metabolism, inflammation, and insulin resistance are key pathological features of both diseases. For many years, it was generally considered that the brain was insensitive to insulin, but it is now accepted that this hormone has central neuromodulatory functions, including roles in learning and memory, that are impaired in AD. However, until recently, the molecular mechanisms accounting for brain insulin resistance in AD have remained elusive. Here, we review recent evidence that sheds light on how brain insulin dysfunction is initiated at a molecular level and why abnormal insulin signaling culminates in synaptic failure and memory decline. We also discuss the cellular basis underlying the beneficial effects of stimulation of brain insulin signaling on cognition. Discoveries summarized here provide pathophysiological background for identification of novel molecular targets and for development of alternative therapeutic approaches in AD. © 2014 The Alzheimer's Association. All rights reserved.

Author-supplied keywords

  • Alzheimer's disease
  • Amyloid-β oligomers
  • GLP-1R agonists
  • Insulin resistance
  • Insulin therapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Fernanda G. De Felice

  • Mychael V. Lourenco

  • Sergio T. Ferreira

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free